AIA Group Ltd Purchases 134,452 Shares of Edwards Lifesciences Co. (NYSE:EW)

AIA Group Ltd lifted its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 28.8% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 601,745 shares of the medical research company’s stock after buying an additional 134,452 shares during the quarter. Edwards Lifesciences comprises 1.9% of AIA Group Ltd’s holdings, making the stock its 10th biggest position. AIA Group Ltd owned 0.10% of Edwards Lifesciences worth $45,883,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Edwards Lifesciences by 0.6% in the third quarter. Vanguard Group Inc. now owns 51,633,416 shares of the medical research company’s stock worth $3,577,163,000 after purchasing an additional 325,808 shares during the period. Alliancebernstein L.P. increased its holdings in Edwards Lifesciences by 0.3% in the 2nd quarter. Alliancebernstein L.P. now owns 20,512,235 shares of the medical research company’s stock valued at $1,934,919,000 after buying an additional 66,763 shares during the period. Wellington Management Group LLP raised its position in shares of Edwards Lifesciences by 9.2% in the 3rd quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock valued at $1,138,575,000 after buying an additional 1,390,427 shares in the last quarter. Moneta Group Investment Advisors LLC lifted its holdings in shares of Edwards Lifesciences by 104,971.3% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company’s stock worth $1,148,938,000 after acquiring an additional 15,384,593 shares during the period. Finally, Brown Advisory Inc. lifted its holdings in shares of Edwards Lifesciences by 5.7% during the 3rd quarter. Brown Advisory Inc. now owns 15,133,146 shares of the medical research company’s stock worth $1,048,424,000 after acquiring an additional 818,849 shares during the period. Institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Mizuho lifted their price target on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. Citigroup increased their price objective on Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a report on Wednesday, April 3rd. Wells Fargo & Company raised Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 target price on the stock in a report on Friday, February 2nd. Truist Financial increased their price target on Edwards Lifesciences from $78.00 to $84.00 and gave the company a “buy” rating in a research note on Friday, December 22nd. Finally, StockNews.com lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $91.73.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock traded down $0.84 during mid-day trading on Thursday, reaching $86.40. The company’s stock had a trading volume of 2,089,578 shares, compared to its average volume of 3,848,971. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12. The company has a market capitalization of $52.01 billion, a P/E ratio of 37.93, a PEG ratio of 4.46 and a beta of 1.05. The firm’s fifty day moving average price is $90.12 and its two-hundred day moving average price is $78.14.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.64. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The firm’s revenue was up 13.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.64 EPS. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Catherine M. Szyman sold 27,000 shares of Edwards Lifesciences stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total value of $2,311,740.00. Following the completion of the sale, the vice president now owns 34,814 shares of the company’s stock, valued at approximately $2,980,774.68. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $92.32, for a total value of $1,329,408.00. Following the transaction, the vice president now directly owns 173,849 shares in the company, valued at $16,049,739.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Catherine M. Szyman sold 27,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total value of $2,311,740.00. Following the transaction, the vice president now owns 34,814 shares of the company’s stock, valued at approximately $2,980,774.68. The disclosure for this sale can be found here. Insiders have sold a total of 194,004 shares of company stock valued at $17,166,254 in the last ninety days. 1.29% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.